Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer
Show others and affiliations
2010 (English)In: BMC Cancer, ISSN 1471-2407, E-ISSN 1471-2407, Vol. 10, 125- p.Article in journal (Refereed) Published
Abstract [en]

Background: Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer. Methods: HMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA) consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk of recurrence free survival (RFS). Results: Seventy-two tumours were suitable for analysis. Cytoplasmic HMG-CoAR expression was present in 65% (n = 46) of tumours. No relationship was seen between HMG-CoAR and age, histological subtype, grade, disease stage, estrogen receptor or Ki-67 status. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS (p = 0.012). Multivariate Cox regression analysis revealed that HMG-CoAR expression was an independent predictor of improved RFS (RR = 0.49, 95% CI (0.25-0.93); p = 0.03) when adjusted for established prognostic factors such as residual disease, tumour stage and grade. Conclusion: HMG-CoAR expression is an independent predictor of prolonged RFS in primary ovarian cancer. As HMG-CoAR inhibitors, also known as statins, have demonstrated anti-neoplastic effects in vitro, further studies are required to evaluate HMG-CoAR expression as a surrogate marker of response to statin treatment, especially in conjunction with current chemotherapeutic regimens.

Place, publisher, year, edition, pages
2010. Vol. 10, 125- p.
Keyword [en]
REDUCTASE EXPRESSION, PERILLYL ALCOHOL, CELL-CYCLE, STATIN USE, FOLLOW-UP, RISK, MEVALONATE, INHIBITION, LOVASTATIN
National Category
Medical and Health Sciences Biological Sciences
Identifiers
URN: urn:nbn:se:kth:diva-28289DOI: 10.1186/1471-2407-10-125ISI: 000276817100001Scopus ID: 2-s2.0-77950540366OAI: oai:DiVA.org:kth-28289DiVA: diva2:386987
Funder
Knut and Alice Wallenberg Foundation
Note
QC 20110113Available from: 2011-01-13 Created: 2011-01-12 Last updated: 2017-12-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopus

Authority records BETA

Uhlén, Mathias

Search in DiVA

By author/editor
Uhlén, Mathias
By organisation
Proteomics
In the same journal
BMC Cancer
Medical and Health SciencesBiological Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 34 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf